Psilocybin
Asset
Converted to psilocin, which activates serotonin 5-HT2A receptors.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- HTR2A
- 3
- Indications
- 1
- Trial
- 1
- Developer
Indications
3Aging
Phase 1, Not yet recruiting, NCT07719088, clinicaltrials.gov, 15 Oct 2026
Biomarkers of aging
Phase 1, Not yet recruiting, NCT07719088, clinicaltrials.gov, 15 Oct 2026
Longevity
Phase 1, Not yet recruiting, NCT07719088, clinicaltrials.gov, 15 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors11
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.